mirabegron vs tamsulosin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of mirabegron and tamsulosin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Drug interaction studies were conducted in adult patients to investigate the effect of coadministered drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of coadministered drugs (e.g., ketoconazole, rifampin, solifenacin succinate, tamsulosin, and oral contraceptives) [see Clinical Pharmacology ( 12.3 )] .
Myrbetriq
Flomax
Mirabegron is a medicine that helps control an overactive bladder. It relaxes the bladder muscle, allowing it to hold more urine.
Tamsulosin (Flomax) helps to improve urination in men with enlarged prostate glands. It relaxes the muscles in the prostate and bladder, making it easier to urinate.
Mirabegron treats overactive bladder (OAB) in adults. OAB can cause you to feel a frequent and urgent need to urinate. It can also lead to accidental urine leakage (urge urinary incontinence).
This medicine treats the symptoms of an enlarged prostate, also known as benign prostatic hyperplasia (BPH). BPH can cause problems with urination, like difficulty starting or stopping the flow of urine. Tamsulosin helps to relieve these symptoms.
Mirabegron is a beta-3 adrenergic agonist. It works by relaxing the bladder muscle. This helps increase the bladder's capacity to store urine and reduces the urge to go.
Tamsulosin blocks alpha-1 adrenoceptors in the prostate and bladder. These receptors control muscle tightness. By blocking them, tamsulosin relaxes the muscles, which improves urine flow.
- • High blood pressure
- • Common cold symptoms (nasopharyngitis)
- • Urinary tract infection
- • Headache
- • Headache
- • Dizziness
- • Runny nose
- • Infection
- • Abnormal ejaculation
- Fatigue 2,215
- Headache 2,162
- Dizziness 2,093
- Fall 1,892
- Diarrhoea 1,861
- Fatigue 1,417
- Dyspnoea 1,332
- Dizziness 1,131
- Diarrhoea 1,121
- Headache 883
Mirabegron can raise your blood pressure. Your doctor should check your blood pressure regularly, especially if you have high blood pressure. Mirabegron is not recommended if you have severe, uncontrolled high blood pressure (180/110 mm Hg or higher). Use caution if you have bladder outlet obstruction or are taking other medicines for overactive bladder, as it can increase the risk of urinary retention. Angioedema (swelling of the face, lips, tongue, or throat) has been reported.
Tamsulosin can cause a sudden drop in blood pressure when you stand up, leading to dizziness or fainting. Avoid situations where you could get hurt if you faint. Tell your eye doctor if you are planning to have cataract or glaucoma surgery, as tamsulosin can cause complications during the procedure. You should be screened for prostate cancer before starting tamsulosin and regularly after.
It is not known if mirabegron can harm an unborn baby. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
This medicine is only for men. It is not meant to be used by women. There is no information about the safety of tamsulosin during pregnancy or breastfeeding because it is not used in women.
Also Compare, Nearby Drugs
Compare mirabegron with
Compare tamsulosin with
How to Read This mirabegron vs tamsulosin Comparison
mirabegron is classified in the Beta-3 Agonist (Overactive Bladder) drug class, while tamsulosin sits within the Alpha-1 Adrenergic Blocker class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, mirabegron has 10,223 submissions while tamsulosin has 5,884. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to studies show that these two drugs do not significantly change how the body handles either medication.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for mirabegron or tamsulosin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.